VPS9D1

Across TCGA pan-cancer cohorts, VPS9D1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated VPS9D1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher VPS9D1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated VPS9D1 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

READ, LUAD, and STAD are the cancer types where VPS9D1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	All	0.269	0.819	.009	15	view →
LUAD	OS	Median	All	0.275	0.813	<.001	12	view →
STAD	OS	Median	II,III,IV	1.000	0.642	.030	6	view →
ESCA	OS	Median	II,III,IV	0.414	0.699	.016	6	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

VPS9D1–READ (DFS)

Open the READ breakdown →